Patents Examined by Susanna Moore
  • Patent number: 11685740
    Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: June 27, 2023
    Assignee: Shionogi & Co., Ltd.
    Inventors: Koji Masuda, Shuichi Sugiyama, Toru Yamada, Eiichi Kojima, Tomoyuki Ogawa, Naotake Kobayashi, Hiroyuki Kai
  • Patent number: 11685743
    Abstract: Disclosed herein are compound capable of exploiting non-bonding electron densities, for example, cationic open-shell, pi-conjugated bisphenalenyls wherein intermolecular covalent bonding interactions can occur in multiple dimensions. Further disclosed are compositions comprising the disclosed compounds and process for the preparation thereof.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: June 27, 2023
    Inventors: Mark Chen, Caleb Wehrmann, Ryan Charlton
  • Patent number: 11667629
    Abstract: The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: June 6, 2023
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jinming Liu, Jiaqiang Cai, Yongyong Wu, Wei Yin, Lichun Wang, Jingyi Wang
  • Patent number: 11661437
    Abstract: Steroid derivative regulators, a method for preparing the same, and uses thereof are described. Specifically, a compound as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases are described, wherein the substituents of the formula (I) are as defined in the description.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: May 30, 2023
    Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.
    Inventors: Yidong Su, Xiaopo Chen, Jun Wang, Rudi Bao
  • Patent number: 11655217
    Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising the same. The compounds and compositions are useful as modulators of monoacylglycerol lipase (MAGL). Furthermore, the compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: May 23, 2023
    Assignee: H. LUNDBECK A/S
    Inventors: Cheryl A. Grice, John J. M. Wiener, Olivia D. Weber, Katharine K. Duncan
  • Patent number: 11649236
    Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: May 16, 2023
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yoshiyuki Taoda, Yuto Unoh
  • Patent number: 11643434
    Abstract: Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: May 9, 2023
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Maria Jesus Blanco-Pillado, Marshall Lee Morningstar
  • Patent number: 11643409
    Abstract: Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3?R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3?-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.
    Type: Grant
    Filed: August 12, 2022
    Date of Patent: May 9, 2023
    Assignee: Renexxion, LLC
    Inventors: Pascal Jean Druzgala, Jien Heh Tien
  • Patent number: 11639346
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5, L1, L2, E, m1 and m2 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: May 2, 2023
    Assignee: ARAXES PHARMA LLC
    Inventors: Liansheng Li, Jun Feng, Tao Wu, Yuan Liu, Yi Wang, Pingda Ren, Yi Liu
  • Patent number: 11639358
    Abstract: The present invention relates to a process for preparing optically active 1,4-cineole derivatives by enzymatic resolution and enantiomerically pure optically active 1,4-cineole derivatives of purity greater than 99.9% that have been prepared by this process. The present invention further relates to a process for preparing 7-oxabicyclo[2.2.1]heptane derivatives from the enantiomerically pure optically active 1,4-cineole derivatives.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: May 2, 2023
    Assignee: BASF AGRO B.V.
    Inventors: Klaus Ditrich, Michael Rack, Stefan Benson, Roland Goetz, Helmut Kraus
  • Patent number: 11634453
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: April 25, 2023
    Assignee: Sage Therapeutics, Inc.
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
  • Patent number: 11634452
    Abstract: The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 25, 2023
    Assignees: ETHNODYNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Chérif Rabhi, Léon Cariel, Christian Da Costa Noble, Jamal Ouazzani, Guillaume Arcile, Géraldine Le Goff
  • Patent number: 11629167
    Abstract: The present disclosure relates to Betulastatin compounds, pharmaceutical compositions and kits comprising such compounds, and methods for using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: April 18, 2023
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: George R. Pettit, Noeleen Melody
  • Patent number: 11623933
    Abstract: The present invention relates to process for the preparation of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl )carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1?,2?:4,5] pyrazino[2,1-b] [1,3] oxazepin-8-olate of Formula-I and its polymorphic form thereof.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 11, 2023
    Assignee: Honour Lab Limited
    Inventors: Kura Rathnakar Reddy, Kesireddy Subhash Chander Reddy, Guda Yadav Reddy
  • Patent number: 11618766
    Abstract: Disclosed in the present disclosure is a method for preparing 16alpha-hydroxyprednisolone, belonging to the technical field of medicine preparation and processing. In the method, 21-hydroxypregna-1,4,9(11),16-tetraene-3,20-dione-21-acetate is used as a starting material, and subjected to oxidation, bromo-hydroxylation, debromination and alcoholysis, so as to prepare 16alpha-hydroxyprednisolone. The method for preparing 16alpha-hydroxylprednisolone of the present disclosure can effectively control the generation of impurities in the reaction process by improving the disadvantages of traditional processes, and has a mild reaction process and a high overall conversion rate; and the method of the present disclosure has low requirements for a reaction device and low operation costs, is easy to operate, is suitable for industrial production, and has a good market prospect.
    Type: Grant
    Filed: September 20, 2022
    Date of Patent: April 4, 2023
    Assignee: ZHEJIANG SHENZHOU PHARMACEUTICAL COMPANY LIMITED
    Inventors: Zhenping Shao, Rong Wang, Kegang Chen, Bingqian Wang, Youfu Wang
  • Patent number: 11613555
    Abstract: Methods and systems for making onapristone (ONA) using acidic hydrolysis and dehydration with sulfuric acid in an alcoholic solution are provided.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: March 28, 2023
    Assignee: CONTEXT BIOPHARMA, INC.
    Inventors: Ulf Tilstam, Stefan Proniuk, Ferry Brands
  • Patent number: 11613545
    Abstract: Disclosed in the present invention are a macrocyclic compound serving as a Weel inhibitor, and applications thereof in the preparation of drugs for treating Weel-related diseases. The present invention specifically relates to a compound represented by formula (II), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: March 28, 2023
    Assignee: WUXI BIOCITY BIOPHARMACEUTICS CO., LTD.
    Inventors: Wenyuan Qian, Chundao Yang, Zhengwei Li, Jie Li, Jian Li, Shuhui Chen
  • Patent number: 11608338
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: March 21, 2023
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • Patent number: 11608334
    Abstract: The present invention relates to pyrrolo-aromatic heterocyclic compounds, a preparation method therefor and medical use thereof. Particularly, the present invention relates to a compound represented by formula I, a preparation method therefor, a pharmaceutical composition comprising the compound, and use of the compound as a BTK kinase inhibitor. The compound and the pharmaceutical composition comprising same can be used for the treating diseases associated with BTK kinase activity, such as inflammations, autoimmune disorders, and cancers. The definition of each substituent in formula I is the same as that in the description.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: March 21, 2023
    Assignee: THE NATIONAL INSTITUTES OF PHARMACEUTICAL R&D CO., LTD.
    Inventors: Huijun Yin, Xu Yan, Libin Zong, Weixue Tian, Li Zheng, Haoshuai Dou, Yan Yang
  • Patent number: 11603375
    Abstract: Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: March 14, 2023
    Assignee: ZOMAGEN BIOSCIENCES LTD
    Inventors: Raju Mohan, John Nuss, Jason Harris, Shendong Yuan